FDA Approves FINGOLIMOD — Alembic Pharmaceuticals Inc.

# FDA Approves Generic Fingolimod; Alembic Pharmaceuticals Enters Multiple Sclerosis Market The FDA has approved Alembic Pharmaceuticals Inc.'s generic fingolimod hydrochloride oral formulation, potentially intensifying competition in the multiple sclerosis treatment market and creating pricing pressure on Novartis's branded Gilenya. The approval could provide patients with a more affordable treatment option while allowing Alembic to capture market share in a therapeutic category valued at hundreds of millions of dollars annually.